Reducing capsular thickness and enhancing angiogenesis around implant drug release systems.
Biological encapsulation and the foreign body reaction can impair the performance of implanted drug release devices. In this article, the classic definition of biocompatibility is questioned. Examples are presented of biomaterials showing unique healing behavior. A new paradigm for biomaterials healing is proposed in which non-specific protein adsorption is inhibited and matricellular proteins are controlled at the surfaces of implants.
Ratner
Buddy D
BD
University of Washington Engineered Biomaterials (UWEB), RM 484, Bagley Hall, Seattle, WA 98195-1720, USA. ratner@uweb.engr.washington.edu
D000818:Animals; D001672:Biocompatible Materials; D016503:Drug Delivery Systems; D004343:Drug Implants; D005549:Foreign-Body Reaction; D006801:Humans; D018919:Neovascularization, Physiologic; D015676:Osteonectin / Q000502:physiology; D053495:Osteopontin; D012795:Sialoglycoproteins / Q000502:physiology; D019699:Thrombospondins / Q000502:physiology; D000099262:Thrombospondin 2
D001672:Biocompatible Materials; D004343:Drug Implants; D015676:Osteonectin; D053495:Osteopontin; D012795:Sialoglycoproteins; D019699:Thrombospondins; D000099262:Thrombospondin 2; C506895:SPP1 protein, human